ARGENX SEARGXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
ARGX Q4 FY2025 Key Financial Metrics
Revenue
$2.5B
Gross Profit
$2.2B
Operating Profit
$713.8M
Net Profit
$877.2M
Gross Margin
89.5%
Operating Margin
28.9%
Net Margin
35.5%
YoY Growth
83.2%
EPS
$13.25
ARGENX SE Q4 FY2025 Financial Summary
ARGENX SE reported revenue of $2.5B (up 83.2% YoY) for Q4 FY2025, with a net profit of $877.2M (up 1.3% YoY) (35.5% margin). Cost of goods sold was $259.1M, operating expenses totaled $1.5B.
Key Financial Metrics
| Total Revenue | $2.5B |
|---|---|
| Net Profit | $877.2M |
| Gross Margin | 89.5% |
| Operating Margin | 28.9% |
| Report Period | Q4 FY2025 |
ARGENX SE Quarterly Revenue & Net Profit History
ARGENX SE results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.5B | +83.2% | $877.2M | 35.5% |
| Q2 FY2025 | $1.8B | +96.7% | $414.8M | 23.4% |
| Q4 FY2024 | $1.4B | — | $865.6M | 64.1% |
| Q2 FY2024 | $901.9M | +76.5% | $-32.5M | -3.6% |
| Q2 FY2023 | $510.9M | +337.9% | $-123.2M | -24.1% |
Income Statement
| Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Revenue | $510.9M | $901.9M | $1.35B | $1.77B | $2.47B |
| YoY Growth | 337.9% | 76.5% | N/A | 96.7% | 83.2% |
Balance Sheet
| Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Assets | $3.19B | $4.80B | $6.20B | $7.18B | $8.68B |
| Liabilities | $335.7M | $534.3M | $704.2M | $1.08B | $1.36B |
| Equity | $2.86B | $4.26B | $5.50B | $6.10B | $7.32B |
Cash Flow
| Q2 2023 | Q2 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Operating CF | $-285.4M | $-124.7M | $41.9M | $361.8M | $323.3M |